secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001818382-23-000112
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte Q2 net loss $22.7M; vascular trauma trial enrollment complete, BLA on track
--------------------------------------------------------------------------------

- Completed enrollment in Phase 2/3 V005 trauma trial (68 patients, 51 for efficacy); top-line results expected Q3 2023.
- BLA filing for HAV in vascular trauma planned Q4 2023; received RMAT designation in May 2023.
- Cash $114.6M; up to $160M Oberland funding ($40M received); funds operations past potential approval.
- Net loss $22.7M vs net income $36.9M in Q2 2022; increase due to non-cash remeasurement of contingent earnout.
- Ukraine humanitarian program: 19 patients, 95% 30-day patency, 100% limb salvage, 0 infections.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838223000112/0001818382-23-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838223000112/huma-20230814.htm
  HTML page:      https://secwatch.observer/filing/0001818382-23-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer